10 results on '"Nisticò, S."'
Number of results to display per page
Search Results
2. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
- Author
-
Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, and Patruno C
- Subjects
- Adult, Antibodies, Monoclonal, Humanized adverse effects, Drug Eruptions immunology, Eczema chemically induced, Eczema immunology, Female, Humans, Interleukin-17 immunology, Male, Middle Aged, Psoriasis immunology, Retrospective Studies, Young Adult, Dermatologic Agents adverse effects, Drug Eruptions diagnosis, Eczema diagnosis, Interleukin-17 antagonists & inhibitors, Psoriasis drug therapy
- Published
- 2019
- Full Text
- View/download PDF
3. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
- Author
-
Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, and Nisticò S
- Subjects
- Administration, Cutaneous, Calcineurin Inhibitors adverse effects, Dermatologic Agents adverse effects, Humans, Immunosuppressive Agents adverse effects, Psoriasis diagnosis, Psoriasis immunology, Skin immunology, Skin pathology, Tacrolimus administration & dosage, Tacrolimus adverse effects, Treatment Outcome, Calcineurin Inhibitors administration & dosage, Dermatologic Agents administration & dosage, Immunosuppressive Agents administration & dosage, Psoriasis drug therapy, Skin drug effects, Tacrolimus analogs & derivatives
- Abstract
Inverse psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. Topical calcineurin inhibitors are indicated for the treatment of atopic dermatitis but have also been studied in the treatment of psoriasis. The object of the present study is to define the efficacy of topical calcineurin inhibitors in the treatment of psoriasis. We checked for English-vernacular articles conveyed since 1990 in PubMed, Ovid/Cochrane, and Embase using "tacrolimus," "pimecrolimus," or "topical calcineurin inhibitors," and "psoriasis" as keywords. Eight double-blind studies and seven open studies displayed the ampleness of topical tacrolimus in psoriasis. Included studies demonstrated a considerable efficacy of topical administration of tacrolimus and pimecrolimus in the treatment of psoriasis, especially for facial, genital, and intertriginous areas. The role of topical tacrolimus and pimecrolimus in the treatment of psoriasis seems to be promising as shown by the results of double-blind and open studies. Because these agents do not cause cutaneous atrophy, they have a special role in facial, genital, and intertriginous psoriatic lesions. Both agents await additional investigation to determine their roles., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
4. A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis.
- Author
-
Nisticò SP, Saraceno R, Stefanescu S, and Chimenti S
- Subjects
- Dose-Response Relationship, Radiation, Female, Humans, Male, Middle Aged, Treatment Outcome, Foot Dermatoses radiotherapy, Hand Dermatoses radiotherapy, Psoriasis radiotherapy, Ultraviolet Therapy methods
- Abstract
Background: Various reports have shown the efficacy of narrow-band UVB (311-313 nm) and excimer laser (308 nm) in the treatment of psoriasis., Objective: To prove the efficacy of light produced by xenon-chloride excimer at 308 nm (monochromatic excimer light, MEL) in the treatment of palmoplantar psoriasis (PP)., Methods: Fifty-four patients (29 male and 25 female) affected by PP were treated with MEL every 7-14 days. A mean number of 10 sessions was performed with an increase of the dose depending on patient's skin type and response., Results: All 54 patients completed the treatment. After 4 months of MEL we observed a complete remission in 31 patients, a partial remission in 13 patients, and a moderate improvement in 10 patients., Conclusions: These results suggest that MEL can be considered as a valid therapeutic option for treatment of selected forms of PP.
- Published
- 2006
- Full Text
- View/download PDF
5. Safety and efficacy study on etanercept in patients with plaque psoriasis.
- Author
-
Costanzo A, Mazzotta A, Papoutsaki M, Nisticò S, and Chimenti S
- Subjects
- Adult, Aged, Etanercept, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Immunoglobulin G therapeutic use, Psoriasis drug therapy, Receptors, Tumor Necrosis Factor therapeutic use
- Published
- 2005
- Full Text
- View/download PDF
6. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population.
- Author
-
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nisticò S, Chimenti S, Pallone F, and Novelli G
- Subjects
- Alleles, Base Sequence, Case-Control Studies, Female, Gene Frequency, Genetic Linkage, Humans, Italy epidemiology, Male, Molecular Sequence Data, Nod2 Signaling Adaptor Protein, Polymerase Chain Reaction, Probability, Psoriasis epidemiology, Reference Values, Severity of Illness Index, Carrier Proteins genetics, Genetic Predisposition to Disease, Intracellular Signaling Peptides and Proteins, Mutation, Polymorphism, Genetic, Psoriasis genetics
- Abstract
Psoriasis is a chronic inflammatory skin disorder showing multifactorial inheritance. Linkage studies have mapped disease susceptibility loci to several genomic regions, including the chromosome 16 interval that contains the CARD15/NOD2 gene. CARD15 has been involved in Crohn's Disease (CD) susceptibility and it has been hypothesised that it may also contribute to the pathogenesis of psoriasis. To test this hypothesis we studied the distribution of 3 CARD15 SNPs in an Italian case-control data set. We failed to observe any significant difference between patients and controls, thereby excluding the presence of a strong genetic association between CARD15 gene polymorphisms and psoriasis, in the Italian population.
- Published
- 2002
7. Role of TH17 in the pathogenesis of cutaneous inflammatory diseases
- Author
-
Chiricozzi, A., Zhang, S., annunziata dattola, Gabellini, M., Chimenti, S., and Nisticò, S. P.
- Subjects
Inflammation ,IL-17 ,Interleukin-17 ,Animals ,Humans ,Th17 Cells ,Psoriasis ,Allergic contact dermatitis ,Th17 ,Dermatitis, Contact ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Dermatitis, Atopic ,Atopic dermatitis - Abstract
Th17 cells are a new T-cell subtype characterized by the capability of producing IL-17. They are reported to be involved in a wide range of cutaneous immune-mediated conditions and, particularly in this review, we sought to elucidate the Th17 role in the pathogenesis of some common inflammatory diseases including psoriasis, allergic contact dermatitis and atopic dermatitis.
- Published
- 2012
8. 308 nm monochromatic excimer light in the treatment of psoriasis
- Author
-
Nisticò, S. P., Saraceno, R., Schipani, C., Antonio Costanzo, and Chimenti, S.
- Subjects
308 nm ,Settore MED/35 - Malattie Cutanee e Veneree ,MEL ,Psoriasis
9. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population
- Author
-
Borgiani, P., Vallo, L., D Apice, M. R., Giardina, E., Pucci, S., Francesca Capon, Nisticò, S., Chimenti, S., Pallone, F., and Novelli, G.
- Subjects
Male ,Polymorphism, Genetic ,Base Sequence ,Genetic Linkage ,Molecular Sequence Data ,Intracellular Signaling Peptides and Proteins ,Nod2 Signaling Adaptor Protein ,Polymerase Chain Reaction ,Severity of Illness Index ,Gene Frequency ,Italy ,Settore MED/03 - Genetica Medica ,Reference Values ,Case-Control Studies ,Mutation ,Humans ,Psoriasis ,Female ,Genetic Predisposition to Disease ,Carrier Proteins ,Alleles ,Probability - Abstract
Psoriasis is a chronic inflammatory skin disorder showing multifactorial inheritance. Linkage studies have mapped disease susceptibility loci to several genomic regions, including the chromosome 16 interval that contains the CARD15/NOD2 gene. CARD15 has been involved in Crohn's Disease (CD) susceptibility and it has been hypothesised that it may also contribute to the pathogenesis of psoriasis. To test this hypothesis we studied the distribution of 3 CARD15 SNPs in an Italian case-control data set. We failed to observe any significant difference between patients and controls, thereby excluding the presence of a strong genetic association between CARD15 gene polymorphisms and psoriasis, in the Italian population.
10. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study
- Author
-
Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.
- Subjects
0301 basic medicine ,Male ,Clinical Biochemistry ,Disease ,Cohort Studies ,0302 clinical medicine ,Drug Discovery ,Receptors ,80 and over ,Medicine ,Aged, 80 and over ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,Interleukin-17 ,psoriasis ,Middle Aged ,dermatology ,sars-CoV-2 ,Italy ,biological therapy ,030220 oncology & carcinogenesis ,Cohort ,Biological Product ,COVID-19 ,Female ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Adult ,Aged ,Biological Products ,Biological Therapy ,Chronic Disease ,Humans ,Pandemics ,Psoriasis ,Receptors, Interleukin ,Risk Assessment ,Tumor Necrosis Factor-alpha ,Young Adult ,Cohort study ,Human ,medicine.medical_specialty ,Population ,03 medical and health sciences ,Settore MED/35 ,Internal medicine ,education ,Pharmacology ,Psoriasi ,Pandemic ,business.industry ,Biological product ,Interleukin ,medicine.disease ,Clinical trial ,030104 developmental biology ,SARS-CoV-2 ,Cohort Studie ,business - Abstract
Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
- Published
- 2021
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.